Four experts will discuss key considerations when making surgical decisions for cirrhotic patients during Tuesday’s DDW® Clinical Symposium, Cirrhosis and Surgery: Identifying and Managing, which
Four experts will help clinicians take the uncertainty out of the diagnosis and management of incidental liver lesions during Monday’s DDW® Clinical Symposium, Incidental Liver
Six cutting-edge abstracts will be presented during Sunday afternoon’s AASLD Plenary Session, which will be moderated by AASLD President Anna S. Lok, MD, FAASLD, and AASLD Secretary Kimberly A. Brown, MD, FAASLD.
In the last decade, considerable time and resources have been devoted to hepatitis C research, leading to significant treatment breakthroughs.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury (DILI) Network to collect and analyze cases of severe liver injury caused by prescription drugs, herbal products and supplements.
Current treatments for hepatitis C virus (HCV) are quite effective, with a cure rate inching toward 100 percent. However, there are certain subpopulations that fail direct-acting antiviral (DAA) therapy and others who have yet to be diagnosed — up to 50 percent of people with the virus, according to some estimates.
A recent analysis published in the journal HEPATOLOGY suggests that the global prevalence of nonalcoholic fatty liver disease (NAFLD) is about 25 percent. According to
Expert teams will tackle two of the most controversial topics in hepatology and GI endoscopy during Monday’s AASLD Academic Debates session, providing attendees with a
Renowned experts in the field of hepatology will review the most recent treatment and research advances in chronic liver disease during the annual AASLD Hepatology
AASLD’s educational programming at DDW® is designed to provide a broad education in liver disease for the general gastroenterologist, according to AASLD Secretary Kimberly A.
